Osteopontin as a novel prognostic marker in stable ischaemic heart disease: A 3-year follow-up study

European Journal of Clinical Investigation

Volumn 40, Issue 4, 2010, Pages 288-293

  Georgiadou, Panagiota ^a   Iliodromitis, Efstathios K ^a   Kolokathis, Fotios ^a   Varounis, Christos ^a   Gizas, Vassilis ^a   Mavroidis, Manolis ^b   Capetanaki, Yassemi ^b   Boudoulas, Harisios ^b   Kremastinos, Dimitrios T ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Biomarkers; Ischaemic heart disease; Osteopontin; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC ACID DERIVATIVE; OSTEOPONTIN; SIMVASTATIN;

ADULT; ADVERSE OUTCOME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CORONARY ARTERY OBSTRUCTION; DISEASE MARKER; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICULOGRAPHY; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REVASCULARIZATION; STABLE ANGINA PECTORIS; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; BIOLOGICAL MARKERS; CORONARY STENOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS;

EID: 77949702401     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02257.x     Document Type: Article

References (28)

1. Sleight P. Current options in the management of coronary artery disease. Am J Cardiol 2003 92 : 4 8.
2. Agema WR, Monraats PS, Zwinderman AH, De Winter RJ, Tio RA, Doevendans PA et al. Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drugeluting stent era. Eur Heart J 2004 25 : 1163 1170.
3. Hasdai D, Behar S, Boyko V, Danchin N, Bassand JP, Battler A. Cardiac biomarkers and acute coronary syndromes - the Euro Heart Survey of Acute Coronary Syndromes Experience. Eur Heart J 2003 24 : 1189 1194.
4. Wiest FC, Bryson CL, Burman M, McDonell MB, Henikoff JG, Fihn SD. Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting. Am J Med 2004 117 : 234 241.
5. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001 107 : 1055 1061.
6. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin-a molecule for all seasons. QJM 2002 95 : 3 13.
7. Okamoto H. Osteopontin and the cardiovascular system. Mol Cell Biochem 2007 300 : 1 7.
8. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest 1994 94 : 1597 1604.
9. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003 170 : 333 337.
10. Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 2006 26 : 1 2.
11. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006 27 : 802 807.
12. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008 1 : 43 9.
13. Riedl M, Vila G, Maier C, Handisurya A, Shakeri-Manesch S, Prager G et al. Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab 2008 93 : 2307 2312.
14. Staal A, Van Wijnen AJ, Desai RK, Pols HA, Birkenhäger JC, Deluca HF et al. Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Endocrinology 1996 137 : 2001 2011.
15. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007 27 : 2302 2309.
16. Xie Z, Singh M, Singh K. ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species-mediated induction of osteopontin gene expression by angiotensin II and interleukin-1beta in adult rat cardiac fibroblasts. J Cell Physiol 2004 198 : 399 407.
17. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. Clin Invest 1996 98 : 2218 2227.
18. Georgiadou P, Iliodromitis EK, Varounis C, Mavroidis M, Kolokathis F, Andreadou I et al. Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease. Expert Opin Ther Targets 2008 12 : 917 920.
19. Georgiadou P, Iliodromitis EK, Kolokathis F, Mavroidis M, Andreadou I, Demopoulou M et al. Plasma levels of osteopontin before and 24 hours after percutaneous coronary intervention. Expert Opin Ther Targets 2008 12 : 1477 1480.
20. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW et al. Myocaridal osteopontin expression coincides with the development of heart failure. Hypertension 1999 33 : 663 670.
21. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997 96 : 3063 3071.
22. Mavroidis M, Capetanaki Y. Extensive induction of important mediators of fibrosis and dystrophic calcification in desmin-deficient cardiomyopathy. Am J Pathol 2002 160 : 943 952.
23. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004 24 : 1161 1170.
24. Detrano R, Hsiai T, Wang S, Puentes G, Fallavollita J, Shields P et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol 1996 27 : 285 290.
25. Pass HI, Lott D, Leonardo F, Harbut M, Liu Z, Tang N et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005 353 : 1564 1573.
26. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002 287 : 1671 1679.
27. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J et al. AtheroGene Investigators. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005 26 : 241 249.
28. Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006 6 : 207.